Allogene Therapeutics Inc (NASDAQ: ALLO) is 1.88% higher on its value in year-to-date trading and has touched a low of $1.32 and a high of $5.78 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ALLO stock was last observed hovering at around $2.26 in the last trading session, with the day’s loss setting it -0.09%.
Currently trading at $2.17, the stock is 17.22% and 10.46% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.87 million and changing -3.77% at the moment leaves the stock -11.70% off its SMA200. ALLO registered -53.33% loss for a year compared to 6-month loss of -17.80%.
The stock witnessed a 13.02% gain in the last 1 month and extending the period to 3 months gives it a 0.93%, and is 53.90% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 38.09% over the week and 15.08% over the month.
Allogene Therapeutics Inc (ALLO) has around 233 employees, a market worth around $454.99M and $0.04M in sales. Profit margin for the company is -659137.21%. Distance from 52-week low is 64.39% and -62.42% from its 52-week high. The company has generated returns on investments over the last 12 months (-51.64%).
with sales reaching $10.5k over the same period.The EPS is expected to grow by 36.25% this year, but quarterly earnings will post -68.42% year-over-year. Quarterly sales are estimated to shrink -50.00% in year-over-year returns.
Allogene Therapeutics Inc (ALLO) Top Institutional Holders
The shares outstanding are 209.50M, and float is at 134.72M with Short Float at 23.79%.
The top institutional shareholder in the company is FMR LLC with over 31.26 million shares valued at $72.83 million. The investor’s holdings represent 16.4491% of the ALLO Shares outstanding. As of 2024-06-30, the second largest holder is TPG GP A, LLC with 18.72 million shares valued at $$43.61 million to account for 9.8493 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 16.45 million shares representing 9.7238% and valued at over $38.32 million, while VANGUARD GROUP INC holds 4.8458 of the shares totaling 8.2 million with a market value of $19.1 million.
Allogene Therapeutics Inc (ALLO) Insider Activity
The most recent transaction is an insider sale by MESSEMER DEBORAH M.,the company’sDirector. SEC filings show that MESSEMER DEBORAH M. sold 13,313 shares of the company’s common stock on Feb 18 ’25 at a price of $2.43 per share for a total of $32351.0. Following the sale, the insider now owns 0.14 million shares.
Still, SEC filings show that on Feb 03 ’25, Douglas Earl Martin (SVP, General Counsel) disposed off 6,404 shares at an average price of $1.71 for $10951.0. The insider now directly holds 587,848 shares of Allogene Therapeutics Inc (ALLO).
